Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy

Jeremy P. McGale,Harrison J. Howell,Arnaud Beddok,Mickael Tordjman,Roger Sun,Delphine Chen,Anna M. Wu,Tarek Assi,Samy Ammari,Laurent Dercle

DOI: https://doi.org/10.3390/ph17020210

IF: 4.6

2024-02-07

Pharmaceuticals

Abstract:The integration of artificial intelligence (AI) and positron emission tomography (PET) imaging has the potential to become a powerful tool in drug discovery. This review aims to provide an overview of the current state of research and highlight the potential for this alliance to advance pharmaceutical innovation by accelerating the development and deployment of novel therapeutics. We previously performed a scoping review of three databases (Embase, MEDLINE, and CENTRAL), identifying 87 studies published between 2018 and 2022 relevant to medical imaging (e.g., CT, PET, MRI), immunotherapy, artificial intelligence, and radiomics. Herein, we reexamine the previously identified studies, performing a subgroup analysis on articles specifically utilizing AI and PET imaging for drug discovery purposes in immunotherapy-treated oncology patients. Of the 87 original studies identified, 15 met our updated search criteria. In these studies, radiomics features were primarily extracted from PET/CT images in combination (n = 9, 60.0%) rather than PET imaging alone (n = 6, 40.0%), and patient cohorts were mostly recruited retrospectively and from single institutions (n = 10, 66.7%). AI models were used primarily for prognostication (n = 6, 40.0%) or for assisting in tumor phenotyping (n = 4, 26.7%). About half of the studies stress-tested their models using validation sets (n = 4, 26.7%) or both validation sets and test sets (n = 4, 26.7%), while the remaining six studies (40.0%) either performed no validation at all or used less stringent methods such as cross-validation on the training set. Overall, the integration of AI and PET imaging represents a paradigm shift in drug discovery, offering new avenues for more efficient development of therapeutics. By leveraging AI algorithms and PET imaging analysis, researchers could gain deeper insights into disease mechanisms, identify new drug targets, or optimize treatment regimens. However, further research is needed to validate these findings and address challenges such as data standardization and algorithm robustness.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to accelerate the drug discovery process by combining artificial intelligence (AI) and positron emission tomography (PET) imaging technology, especially in the field of immunotherapy. Specifically, the paper explores the following aspects:

1. **Target verification**:
- Traditional methods such as tissue biopsy have invasive, temporal and spatial limitations when obtaining molecular target information.
- Can the use of AI and PET imaging more accurately identify and distribute specific molecular targets (such as PD - L1 expression), thereby better guiding personalized treatment?

2. **Safety assessment**:
- Immunotherapy may cause immune - related adverse events (irAEs), such as pneumonia, colitis, etc.
- How to use AI and PET imaging to predict the occurrence of these adverse events to help doctors perform risk stratification and decide whether to continue treatment?

3. **Biomarkers for prognosis and efficacy assessment**:
- In existing clinical trials, patients' responses to immunotherapy vary greatly. How can better biomarkers be found through AI and PET imaging to predict patients' prognosis and treatment response?

4. **Improving drug development efficiency**:
- The current development of immunotherapy drugs faces many challenges, including target verification, safety assessment, biomarker selection, etc.
- Can AI and PET imaging provide new ways to accelerate the research and development and clinical application of new drugs, so that effective treatment methods can be applied to patients more quickly?

By integrating AI and PET imaging technologies, researchers hope to gain a deeper understanding of disease mechanisms, identify new drug targets, and optimize treatment regimens, ultimately achieving more efficient drug development and more precise patient management.

### Key technologies and methods involved

- **PET imaging**: Quantify in - vivo metabolic activities through radioactive tracers (such as \(^{18}F\)-FDG) to provide information about the tumor metabolic state.
- **AI and radiomics**: Extract features (such as the maximum, mean, and distribution of pixel intensities) from medical images and build prediction models through machine - learning algorithms.
- **Multi - modal image analysis**: Combine PET and CT images to improve the accuracy of feature extraction.

### Conclusion

The paper points out that the combination of AI and PET imaging represents a paradigm shift in the field of drug discovery and provides a new way for more efficient development of new therapeutic drugs. However, further research is still needed to verify these findings and address challenges such as data standardization and algorithm robustness.